Dyslipidemie
Opleiding
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262
Why Don’t We Strike Early, Strike Strong?
Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens
.svg)
